CheckMate 577 Update: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemotherapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Compared with placebo, adjuvant nivolumab significantly prolonged disease-free survival in patients with resected EC/GEJC who had received neoadjuvant chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 392 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

In slides from Clinical Care Options (CCO), experts discuss emerging data surrounding use of immune checkpoint inhibitors for early HCC

Amit G. Singal, MD, MS Released: November 12, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Richard S. Finn, MD Amit G. Singal, MD, MS Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue